Pat Whitworth, MD, FACS, FSSO
Chief Medical Officer, PreludeDx
| 0:00 |
Welcome & Speaker Introductions |
| 2:12 |
Identifying Patient Risk with DCISionRT |
Leona Hamrick, DHSc, PA-C, MSL-BC
Vice President, Global Medical Affairs, PreludeDx
| 10:19 |
DCISionRT Validation Data Summary |
Chirag Shah, MD
Co-Director of the Comprehensive Breast Program and Director of Clinical Research in the Department of Radiation Oncology at Cleveland Clinic
| 21:20 |
Summary of the PREDICT Study |
Eileen Connolly, MD, PhD
Assistant Professor of Radiation Oncology, Co-Lead, Breast Cancer Disease Based TAM, Columbia Irving Medical Center, Herbert Irving Comprehensive Cancer Center
| 28:59 |
Real-World Case Studies |
Roundtable Discussion:
| 44:32 |
Endocrine Therapy |
| 46:56 |
Value of ordering DCISionRT on clinicopathologic low-risk patientsy |
| 49:13 |
Patient preference |
| 50:33 |
Multi-disciplinary collaboration |
